【レポートの概要（一部）】
1. Report Overview
1.1 Next-Generation Antibody Therapies Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why you Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by This Analytical Study
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Next-Generation Antibody Therapies
2.1 Antibodies: An Overview
2.1.1 Monoclonal versus Polyclonal Antibodies
2.1.2 A Brief History of Antibody Drug Development
2.1.3 The Antibody Manufacturing Process
2.1.4 Trends in Antibody Development
2.2 Defining Next-Generation Antibodies
2.3 Classification of Next-Generation Antibody Therapies
2.4 The Need for Next-Generation Technologies
2.5 Development Trends for Next-Generation Antibodies
2.6 Scope of this Report
2.7 Phases of Clinical Trials
3. Next-Generation Antibody Therapies: World Market 2016-2026
3.1 The World Next-Generation Antibody Therapies Market Overview and Segmentation, 2015
3.2 Leading Next-Generation Antibody Therapies
3.3 World Next-Generation Antibody Therapies Market: Sales Forecast 2016-2026
3.4 How Will Segmental Market Shares Change to 2026?
3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2016-2026
4. Leading Regional Markets 2016-2026
4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market, 2015
4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2016-2026
4.3 How Will Regional Market Shares Change to 2026?
4.4 US Next-Generation Antibody Therapies Market 2015-2026
4.5 EU5 Next-Generation Antibody Therapies Market 2016-2026
4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2016-2026
4.7 Latin American Next-Generation Antibody Therapies Market 2016-2026
4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2016-2026
5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2016-2026
5.1 Market Overview, 2016
5.2 Leading ADCs in 2016
5.3 Antibody-Drug Conjugates: Market Forecast 2016-2026
5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2016-2026
5.4.1 Competition for Leading Drugs Will Restrain Growth
5.4.2 Manufacturing ADCs Forms a Challenge
5.5 Adcetris (brentuximab vedotin, Seattle Genetics / Takeda)
5.5.1 Adcetris: Sales 2011-2015
5.5.2 Adcetris Results in AETHERA Trial and Approval for in HL following Stem Cell Transplantation
5.5.3 Expanding Adcetris Indications for Future Revenue Growth
5.5.4 Adcetris Sales Forecast 2016-2026
5.6 Kadcyla (trastuzumab emtansine, Roche)
5.6.1 Mixed Results from Different Clinical Trials
5.6.2 NICE Rejects Kadcyla on Cost Grounds, but it Just Manages to Hold on in the Cancer Drugs Fund List
5.6.3 Kadcyla Sales Forecast 2016-2026
5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)
5.7.1 Mylotarg to be Relaunched?
5.8 Antibody-Drug Conjugate Platforms
5.8.1 Limited Market Opportunity for Radioconjugation
5.8.2 Seattle Genetics’ Platform Accounted for Over 50% of the Pipeline in 2015
5.8.3 ImmunoGen: TAP Technology
5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use
5.8.5 Preclinical Platforms for ADC Development
5.9 ADCs Have Attracted High-Value Deals and will Continue to do so
5.10 Antibody-Drug Conjugates: Pipeline Analysis 2015-2026
5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market
5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
5.11 Antibody-Drug Conjugates: Phase 3 Pipeline
5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)
5.11.1.1 Granted Breakthrough Therapy Designation
5.11.2 Roche Attempting to Expand Kadcyla Indications and also Possesses some Unique ADCs in the Pipeline
5.11.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
5.11.2.2 RG7599/DNIB0600A (anti-NaPi2b) for Ovarian Cancer
5.11.2.3 RG7450/DSTP3086S (anti-STEAP1) for Prostate Cancer
5.12 Antibody-Drug Conjugates: Phase 2 Pipeline
5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
5.12.4 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)
5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
5.12.9 Seattle Genetics’ Phase 1 and Phase 2 ADCs
5.12.9.1 SGN-CD19A (anti-CD19) for DLBCL and ALL
5.12.9.2 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
5.12.9.3 SGN-CD33A: Using a New Cytotoxin and Linker Technology
5.12.9.4 SGN-CD70A (anti-CD70, Seattle Genetics)
5.13 Antibody-Drug Conjugates: Phase 1 Pipeline
5.14 Antibody-Drug Conjugates: Preclinical Pipeline
5.15 Future Developments in ADC Technology
5.15.1 Site-Specific Linkage for Improved Safety Profiles
6. Engineered Antibodies: Market Forecast and Pipeline 2016-2026
6.1 Defining an ‘Engineered Antibody’
6.2 Market Overview 2016, and the Leading Engineered Antibodies
6.3 Leading Engineered Antibodies: Market Forecast 2016-2026
6.4 The Engineered Antibodies Market: Drivers and Restraints 2015-2026
6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
6.5.1 Poteligeo Sales Forecast 2016-2026
6.6 Gazyva / Gazyvaro (obinutuzumab, Roche)
6.6.1 Gazyva as a Challenger in the anti-CD20 Market
6.6.2 Competition beyond Rituxan and Biosimilars
6.6.3 Gazyva Receives Second Approval
6.6.4 Gazyva Sales Forecast 2016-2026
6.7 Engineered Antibodies Platforms
6.7.1 Roche Glycart: GlucoMAb – Glycosylation for Improved ADCC
6.7.2 Kyowa Hakko Kirin: Potelligent – Enhancing ADCC
6.7.3 Glycotope: GlycoExpress
6.7.4 MacroGenics: Fc Optimization
6.7.5 Xencor: XmAb – Modifying Amino Acids in the Fc Domain
6.7.6 Other Platforms for Increased Potency
6.8 Engineered Antibodies: Pipeline Analysis 2016-2026
6.9 Engineered Antibodies: Phase 3 Pipeline
6.9.1 Benralizumab (MedImmune / Kyowa Hakko Kirin)
6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)
6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)
6.9.5 Ublituximab (anti-CD20, TG Therapeutics)
6.10 Engineered Antibodies: Phase 2 Pipeline
6.10.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
6.10.2 Margetuximab (anti-HER2, MacroGenics)
6.10.3 MEDI-551 (anti-CD19, AstraZeneca)
6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
6.10.5 Teplizumab (anti-CD3, MacroGenics)
6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
6.10.7 XmAb5871 (anti-CD19, Xencor)
6.11 Engineered Antibodies: Phase 1 Pipeline
7. Bispecific Antibodies: Market Forecast and Pipeline 2016-2026
7.1 Bispecific Antibodies: Market Overview, 2016
7.2 Bispecific Antibodies: Market Forecast 2016-2026
7.3 The Bispecific Antibodies Market: Drivers and Restraints 2016-2026
7.4 Removab (catumaxomab, Neopharm)
7.4.1 Removab: Sales Forecast 2016-2026
7.5 Blincyto (blinatumomab, Amgen)
7.5.1 Amgen Files a Supplemental Biologics License Application, and the EU approves Blincyto
7.5.2 Blincyto: Sales Forecast 2016-2026
7.6 Bispecific Antibodies Platforms
7.6.1 BiTE Platform: The Current Market Leader
7.6.2 MacroGenics’ DART Platform Holds Promise
7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2016-2026
7.6.4 Other Bispecific Antibody Platforms
7.6.4.1 DuoBodies (Genmab)
7.6.4.2 ImmTAC (Immunocore)
7.7 Bispecific Antibodies: Pipeline Analysis 2015-2026
7.7.1 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
7.7.2 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
7.7.3 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
7.7.4 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
7.7.5 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
7.7.6 SAR156597 (anti-IL-4 and IL-13, Sanofi)
7.7.7 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
7.8 Bispecific Antibodies: Phase 1, Phase 1/2 and Preclinical Pipeline
8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2016-2026
8.1 Antibody Fragments and ALPs: Market Overview, 2016
8.2 Antibody Fragments and ALPs: Market Forecast 2015-2026
8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2016-2026
8.4 Kalbitor (ecallantide, Shire): Shire Completes Acquisition of Dyax and adds Kalbitor to Portfolio
8.4.1 Kalbitor: Sales Forecast 2016-2026
8.5 Antibody Fragments and ALPs Platforms
8.5.1 Single-chain Variable Fragment Platforms
8.5.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
8.5.1.2 Nanobodies: The Smallest Antibody Fragment
8.5.1.3 Ablynx’s Nanobody Platform Has Created Many Clinical Candidates
8.5.1.4 Domain Antibodies: GSK and Crescendo Biologics
8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
8.5.2.1 DARPins: One-Tenth the Size of Antibodies
8.5.2.2 Anticalins (Pieris): Tested in Clinical Trials
8.5.2.3 Affibodies (Affibody)
8.5.2.4 Fynomers (Covagen/Johnson & Johnson)
8.5.2.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development?
8.5.2.6 Adnectins (Bristol-Myers Squibb)
8.5.2.7 AdAlta: i-bodies
8.5.3 Which Platform Will Lead the Market 2016-2026?
8.6 Antibody Fragments and ALPs: Pipeline Analysis 2016-2026
8.6.1 Ablynx Leads the Pipeline with Six Clinical Projects
8.7 Antibody Fragments and ALPs: Phase 3 Pipeline
8.7.1 Caplacizumab (anti-vWF, Ablynx)
8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
8.8 Antibody Fragments and ALPs: Phase 2 Pipeline
8.8.1 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
8.8.2 Ozoralizumab (anti-TNFα, Ablynx )
8.8.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
8.8.4 ESBA1008 (anti-VEGF, Novartis)
8.9 Antibody Fragments and ALPs: Phase 1 Pipeline
8.9.1 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
8.9.2 ALX-0171 (anti-respiratory syncytial virus)
8.9.3 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
8.9.4 Other Phase 1 Candidates, and the Preclinical Pipeline
9. Biosimilar Antibodies: Market Forecast 2016-2026
9.1 Biosimilar Antibodies: Market Overview, 2016
9.2 Leading Biosimilar Antibodies in 2016.
9.3 Biosimilar Antibodies: Market Forecast 2016-2026
9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2016-2026
9.4.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets
9.4.2 Rising Incidence of Cancer will Drive Demand
9.4.3 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
9.4.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?
10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2016-2026
10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
10.1.1 Strengths: The Path Towards Market Acceptance
10.1.2 Weaknesses
10.1.2.1 Challenges Exist With Current Monoclonal Antibody Therapies
10.1.3 Opportunities
10.1.3.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
10.1.4 Threats
10.1.4.1 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
10.2 STEP Analysis of the Next-Generation Antibody Therapies Market
10.2.1 Social Factors: Rising Demand for Cancer Therapies
10.2.1.1 Cancer Incidence Is Rising Rapidly
10.2.1.2 Next-Generation Antibodies for Personalised Medicine
10.2.2 Technological Developments Will Drive Pipeline Growth
10.2.2.1 There Are Many Competing Platforms
10.2.2.2 Manufacturing Challenges Exist for Most Sectors
10.2.2.3 New Analytical Tools for Target Identification and Protein Characterisation
10.2.3 Economic Pressures
10.2.3.1 Next-Generation Antibodies Are High-Cost
10.2.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
10.2.3.3 Next-Generation Launches for Product Lifecycle Management
10.2.4 Political and Regulatory Issues
10.2.4.1 Regulatory Challenges for Biosimilar Antibodies
10.3 Key Targets for Next-Generation Antibody Development 2016-2026
10.3.1 Oncology Is the Lead Indication in All Sectors
10.3.1.1 HER2 and HER3 for Breast Cancer
10.3.1.2 CD19 and CD20 for Lymphoma and Leukaemia
11. Research Interviews
11.1 Interview with Dr Edwin Moses, CEO, Ablynx, Belgium
11.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
11.1.2 Manufacturing Nanobodies
11.1.3 Turning Challenges to Advantages
11.1.4 Nanobodies Are Further Developed than Other Antibody Scaffolds
11.1.5 The Commercial Potential for Nanobodies
11.1.6 Next-Generation Antibodies in China and Other Emerging Markets
11.2 Interview with Tim van Hauwermeiren, CEO, arGEN-X, the Netherlands and Belgium
11.2.1 arGEN-X’s Development Pipeline
11.2.2 Enhancing the Activity of ARGX-111
11.2.3 arGEN-X’s SIMPLE Antibody™ Platform
11.2.4 Commercial Prospects for arGEN-X’s Antibodies
11.2.5 Plans for Growth
11.2.6 Opportunities and Challenges for Next-Generation Antibody Developers
11.2.7 Therapeutic Areas for Manufacturers of Antibody Therapies
11.2.8 Other Trends and Developments in the Market
11.3 Interview with Mersana Therapeutics, Cambridge, Massachusetts, USA
11.3.1 Mersana’s Development Pipeline
11.3.2 Advantages of the Fleximer Platform
11.3.3 Future Plans for Mersana
11.3.4 The Outlook for ADCs in 2015-2026
12. Conclusions
12.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2015-2026
12.2 Current Status of the Market and Leading Segments
12.3 Leading Next-Generation Antibody Therapies Profiled in this Report
12.4 Leading Regional Markets
12.5 Development of the Market to 2026
12.6 Technology Platforms Will Continue to Attract Big Pharma Interest
12.7 Most Developers Continue to Target Cancer
12.8 Strategies for Growth in 2016-2026
【レポート販売概要】
■ タイトル：次世代抗体治療の世界市場予測2016-2026■ 英文：Next-Generation Antibody Therapies Market Forecast 2016-2026
■ 発行日：2016年4月
■ 調査会社：visiongain
■ 商品コード：VGAIN60630
■ 調査対象地域：グローバル
- LiDARドローンの世界市場予測（～2022）The LiDAR drone market was valued at USD 16.1 Million in 2015 and is expected to reach USD 144.6 Million by 2022, at a CAGR of 35.2% between 2016 and 2022. This market growth is attributed to the encouragement from governments and research institutes for the adoption of LiDAR drones. The increasing automation through LiDAR drones and reduction of human efforts drive the growth of the market. LiDAR …
- Trelagliptin (Type 2 Diabetes)：市場予測と分析（～2022）Trelagliptin (Type 2 Diabetes) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new report, “Trelagliptin (Type 2 Diabetes) - Forecast and Market Analysis to 2022”. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and …
- ケイ素の世界市場動向2014/2015The report presents a thorough study of silicon, covering both global and regional markets. It aims to give a proper picture of the market, its trends, perspectives and opportunities. Comprehensive data showing silicon worldwide production, consumption, trade statistics and prices are provided. Each country’s market overview covers the following: silicon production in the country, major manufactur …
- 自閉症障害：市場機会分析及び予測（～2018）OpportunityAnalyzer: Autism Spectrum Disorder - Opportunity Analysis and Forecasts to 2018 Summary Autism Spectrum Disorders (ASD) is a chronically underserved market currently dominated by the two approved drugs, both of which are antipsychotics. There is off-label use of a multitude of other drugs which target different core and non-core symptoms of ASD. Since this disorder can first become appa …
- Pennant Energy Inc.：石油・ガスの開発・生産動向及びコスト分析- 2012Pennant Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - 2012 Summary Pennant Energy Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key …
- 光ファイバー・テスト装置（FOTE）の世界市場：DWDM、OSA、OTDR、OPM、OLS、RFTS、OLTSAbout FOTE Growing use of optical fibers by the telecom, oil and gas, and military and defense industries is driving the global FOTE market. Data transfers are a critical part of a business operation as companies need information to design, build, and develop their business strategies. When a signal is sent through optical fibers, signal loss is inevitable. A simple measurement of the output signa …
- 新生児用人工呼吸器の世界市場2019-2023About this market A preterm birth or premature birth is the birth of a baby before 37 weeks of gestation. The rising incidence of preterm births is the leading cause of infant mortality. Preterm birth rates depend on racial and ethnic differences as well. Owing to the rising number of preterm births and mortality rates, initiatives by the World Health Assembly and UNICEF seek to provide improved o …
- Xバンドレーダーの世界市場The report provides an analysis of the X-band radar market. An increased threat of terrorism, uncertain attacks, insurgent activities, and unconventional military threats have led to an increase in the demand for X-band radar used for detection of moving personnel, missiles, and moving targets. Recent tension in Eastern Europe region, transnational wars, and attacks are the major factors for incre …
- 世界のトランスレスUPS（無停電電源）市場：Global Transformerless UPS Market 2014-2018TechNavio's analysts forecast the Global Transformerless UPS market to grow at a CAGR of 12.2 percent over the period 2013-2018. One of the key factors contributing to this market growth is the low capital expenditure and installation costs of transformerless UPS. The Global Transformerless UPS market has also been witnessing a growing acceptance of next-generation power storage technologies which …
- 対UAV（無人機）防衛システムの世界市場2016-2020About Counter UAV Defense System Counter UAV defense systems detect potential unmanned aerial vehicle (UAV) threats and find application in industries like military, homeland security, and airports. The system is a combination of radars, infrared cameras, and navigators that recognize drones and limit their risk capabilities. Jamming systems and technologies also play a pivotal role to ensure that …
- テトラクロロエチレン(PCE)の世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world perchloroethylene market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a true …
- 世界におけるワイヤレス充電製品の開発動向Despite a long history of development, wireless charging is still in the introduction phase of the product life cycle. However, the launch of Samsung Galaxy S6/S6 Edge and Apple Watch is expected to unleash a rapid growth in the wireless charging market. This report begins with vendors' new products and industry alliances' latest development, followed by an analysis of the supply chain. Major chip …
- Abraxane (Non-Small Cell Lung Cancer)：市場予測と分析（～2022）Abraxane (Non-Small Cell Lung Cancer) -Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC treatment land …
- ウェスタンブロッティング（WB）の世界市場予測：装置、消耗品The western blotting market is expected to reach USD 730.7 Million in 2021 from USD 574.8 Million in 2016, growing at a CAGR of 4.9%. Increasing number of research activities and R&D spending by pharmaceutical and biotechnology companies, rising prevalence of HIV/AIDS, growing proteomics market, growing number of industry-academic research collaborations, increasing demand for personalized medicin …
- ドアストップの世界市場About Door Stops A door stop is used to hold a door open or closed. It is also used to prevent the door from opening too widely and damaging from nearby walls. A door stop can be a thin slat built inside a door from swinging through when closed. TechNavio's analysts forecast the Global Door Stop market to grow at a CAGR of 6.69 percent and 6.92 percent, respectively, in terms of revenue and unit s …
